1-17 of 17
Rui Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism

Pedro Beltran, Simanshu Dhirendra, Rui Xu, Ming Chen, Daniel Czyzyk, Sofia Donovan, Siyu Feng, Cindy Feng, Lijuan Fu, Felice Lightstone, Ken Lin, Anna Maciag, Dwight Nissley, Erin Riegler, Kerstin Sinkevicius, Andrew Stephen, James Stice, David Turner, Bin Wang, Keshi Wang, Yue Yang, Cathy Zhang, Frank McCormick, Eli Wallace
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): RF02-02.
https://doi.org/10.1158/1538-7445.SABCS23-RF02-02
Published: 02 May 2024
View article titled, Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism
Journal Articles

Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding

Anna E. Maciag, James Stice, Bin Wang, Alok Sharma, Albert Chan, Ken Lin, Devansh Singh, Marcin Dyba, Yue Yang, Saman Setoodeh, Brian P. Smith, Dana Rabara, Zuhui Zhang, Erik K. Larsen, Dom Esposito, John Paul Denson, Michela Ranieri, Mary Meynardie, Sadaf Mehdizadeh, Patrick Alexander, Maria Abreu Blanco, David Turner, Rui Xu, Felice C. Lightstone, Kwok Kin Wong, Dhirendra Simanshu, Keshi Wang, Andrew G. Stephen, Kerstin Sinkevicius, Dwight V. Nissley, Eli Wallace, Frank McCormick, Pedro J. Beltran
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): ND07.
https://doi.org/10.1158/1538-7445.AM2024-ND07
Published: 05 April 2024
View article titled, Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding
Journal Articles

Abstract 6307: A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb-adc) targeting cancers co-expressing PD-L1 and CD47

Shumin Liu, Weidong Lyu, Shuqiang Yin, Yang Lei, Qiudong Zhuo, Liling Zheng, Bin Sun, Shuangyu Tan, Lidong Jiang, Teng Zhang, Bo Gao, Rui Xu, Dechang Huang, Yong Li, Zibin Wu, David Wu, Yvonne (Yu) Wen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6307.
https://doi.org/10.1158/1538-7445.AM2023-6307
Published: 04 April 2023
View article titled, Abstract 6307: A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb-adc) targeting cancers co-expressing PD-L1 and CD47
Journal Articles

Abstract 1454: SMAD3 promotes expression and activity of the androgen receptor in prostate cancer

Hee-Young Jeon, Majid Pornour, Hyunju Ryu, Sudeep Khadka, Rui Xu, Jihyun Jang, Deqiang Li, Hegang Chen, Arif Hussain, Ladan Fazli, Martin Gleave, Xuesen Dong, Qianben Wang, Christopher Barbieri, Jianfei Qi
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1454.
https://doi.org/10.1158/1538-7445.AM2023-1454
Published: 04 April 2023
View article titled, Abstract 1454: SMAD3 promotes expression and activity of the androgen receptor in prostate cancer
Journal Articles

Abstract 4000: A novel pegylated bispecific antibody-drug conjugate (P-BsADC) targeting Her2+ cancers with improved efficacy and therapeutic window

Yu (Yvonne) Wen, Shuqiang Yin, Weidong Lyu, Yang Lei, Qiudong Zhuo, Zibin Wu, Bin Sun, Shuangyu Tan, Lidong Jiang, Teng Zhang, Bo Gao, Rui Xu, Yong Li, Liling Zheng, Shumin Liu, David (Dechun) Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4000.
https://doi.org/10.1158/1538-7445.AM2023-4000
Published: 04 April 2023
View article titled, Abstract 4000: A novel pegylated bispecific antibody-drug conjugate (P-BsADC) targeting Her2+ cancers with improved efficacy and therapeutic window
Journal Articles

Abstract 6175: Developing antibody-drug conjugates against cholangiocarcinoma using a novel molecular target

Bing Zhu, Shi-Li Yao, Xin-Yan Wang, Rui Xu, Peng Guo, Jie-Er Ying
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 6175.
https://doi.org/10.1158/1538-7445.AM2022-6175
Published: 15 June 2022
View article titled, Abstract 6175: Developing antibody-drug conjugates against cholangiocarcinoma using a novel molecular target
Journal Articles

Abstract 6174: Developing a novel antibody drug conjugate against cervical cancer

Shili Yao, Bing Zhu, Xinyan Wang, Rui Xu, Tong Yang, Peng Guo, Huarong Tang, Tao Zhu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 6174.
https://doi.org/10.1158/1538-7445.AM2022-6174
Published: 15 June 2022
View article titled, Abstract 6174: Developing a novel antibody drug conjugate against cervical cancer
Journal Articles

Abstract 5242: Rationally designing a radionuclide drug conjugate for heterogeneous genomically stable gastric cancer

Le Yang, Rui Xu, Peng Guo, Heqing Yi, Xiangdong Cheng
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5242.
https://doi.org/10.1158/1538-7445.AM2022-5242
Published: 15 June 2022
View article titled, Abstract 5242: Rationally designing a radionuclide drug conjugate for heterogeneous genomically stable gastric cancer
Journal Articles

Abstract 5293: Rationally developing antibody drug conjugates targeting genomically stable gastric cancer

Rui Xu, Li Yuan, Xiao-Qing Guan, Shi-Li Yao, Bing Zhu, Tong Yang, Chun Liu, Peng Guo, Jiang-Jiang Qin, Xiang-Dong Cheng
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5293.
https://doi.org/10.1158/1538-7445.AM2022-5293
Published: 15 June 2022
View article titled, Abstract 5293: Rationally developing antibody drug conjugates targeting genomically stable gastric cancer
Journal Articles

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

Changxin Wan, Matthew P. Keany, Han Dong, Linah F. Al-Alem, Unnati M. Pandya, Suzan Lazo, Karsten Boehnke, Katherine N. Lynch, Rui Xu, Dominique T. Zarrella, Shengqing Gu, Paloma Cejas, Klothilda Lim, Henry W. Long, Kevin M. Elias, Neil S. Horowitz, Colleen M. Feltmate, Michael G. Muto, Michael J. Worley, Jr, Ross S. Berkowitz, Ursula A. Matulonis, Marisa R. Nucci, Christopher P. Crum, Bo R. Rueda, Myles Brown, Xiaole Shirley Liu, Sarah J. Hill
Journal: Cancer Research
Series: Author Choice
Cancer Res (2021) 81 (1): 158–173.
https://doi.org/10.1158/0008-5472.CAN-20-1674
Published: 04 January 2021
View article titled, Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Open the PDF for Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract P6-12-08: Attitudes of breast cancer associated doctors toward procreation in young patients with early breast cancer

Yuzhu Zhang, Liping Dian, Qianjun Chen, Rui Xu
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-12-08.
https://doi.org/10.1158/1538-7445.SABCS19-P6-12-08
Published: 15 February 2020
View article titled, Abstract P6-12-08: Attitudes of breast cancer associated doctors toward procreation in young patients with early breast cancer
Journal Articles

Abstract 1093: Synergistic action of sorafenib and carfilzomib against hepatocellular carcinoma in vitro and in vivo

Chao Jiang, Rui Xu, Xiao-Xing Li, Hui-Yun Wang, X.F. Steven Zheng
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1093.
https://doi.org/10.1158/1538-7445.AM2017-1093
Published: 01 July 2017
View article titled, Abstract 1093: Synergistic action of sorafenib and carfilzomib against hepatocellular carcinoma <em>in vitro</em> and <em>in vivo</em>
Journal Articles

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Eli M. Wallace, James P. Rizzi, Guangzhou Han, Paul M. Wehn, Zhaodan Cao, Xinlin Du, Tzuling Cheng, Robert M. Czerwinski, Darryl D. Dixon, Barry S. Goggin, Jonas A. Grina, Megan M. Halfmann, Melissa A. Maddie, Sarah R. Olive, Stephen T. Schlachter, Huiling Tan, Bin Wang, Keshi Wang, Shanhai Xie, Rui Xu, Hanbiao Yang, John A. Josey
Journal: Cancer Research
Series: Author Choice
Cancer Res (2016) 76 (18): 5491–5500.
https://doi.org/10.1158/0008-5472.CAN-16-0473
Published: 15 September 2016
View article titled, A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Open the PDF for A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract DDT01-01: PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma

Eli M. Wallace, Zhaodan Cao, Tzuling Cheng, Robert Czerwinski, Darryl D. Dixon, Xinlin Du, Barry Goggin, Jonas Grina, Megan Halfmann, Guangzhou Han, Heli Huang, John A. Josey, Melissa A. Maddie, Sarah Olive, James Rizzi, Stephen T. Schlachter, Hui-Ling Tan, Bin Wang, Keshi Wang, Paul M. Wehn, Shanhai Xie, Rui Xu, Hanbiao Yang
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): DDT01-01.
https://doi.org/10.1158/1538-7445.AM2015-DDT01-01
Published: 01 August 2015
View article titled, Abstract DDT01-01: PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma
Journal Articles

Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy

Stefan D. Gross, Rui Xu, Mark Boys, Kevin Condroski, Lisa DeMeese, Walt E. DeWolf, Brad Fell, John Fischer, Susan Gloor, Michael J. Humphries, Greg Miknis, Kelly Regal, Mareli Rodriguez, Nicholas Raddatz, Kristin Shotts, Georg Topalov, Eli Wallace, John Zuzack, John A. Josey, James Winkler, Kevin Koch
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 4484.
https://doi.org/10.1158/1538-7445.AM10-4484
Published: 15 April 2010
View article titled, Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy
Journal Articles

Abstract #139: Plasma VEGF level after bevacizumab plus chemotherapy treatment is associated with the survival of patients with non-squamous non-small cell lung cancer

She-Juan An, Yi-Long Wu, Chong-Rui Xu, Jian-Guang Chen, Yan Yang, Hai-Yu Zhou
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 139.
Published: 01 May 2009
View article titled, Abstract #139: Plasma VEGF level after bevacizumab plus chemotherapy treatment is associated with the survival of patients with non-squamous non-small cell lung cancer
Journal Articles

Targeting angiogenesis as a cancer prevention strategy

Chong Feng, Caisheng Ye, Xiaoning Liu, Anjia Han, Rui Xu, Mengfeng Li
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1232.
Published: 01 May 2005
View article titled, Targeting angiogenesis as a cancer prevention strategy